After a median follow-up of @ months , PFS was improved in patients who received rituximab/bevacizumab compared with patients who received rituximab alone ( median @ vs. @ months respectively ; HR , @ ( @ % confidence interval -LSB- CI -RSB- , @-@ @ ) ; P = @ ) .